Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.71 |
| ▸ | F3 | P13726 | 1/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | NHERF1 | O14745 | 6/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14631289 | 0.86 | F7 (0.69) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL26054367 | 0.86 | F7 (0.69) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL24143246 | 0.83 | F7 (0.65) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL1434913 | 0.83 | F7 (1.00) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL16920166 | 0.83 | NR4A2 (0.60) | F7F3NR4A2GABRA1GABRB1 | |
| SCHEMBL4035612 | 0.83 | LMNA (0.66) | F7F3NR4A2CDK4CCND1 | |
| SCHEMBL592274 | 0.81 | F7 (0.77) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL3590666 | 0.80 | F7 (0.75) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL23612197 | 0.80 | PRKAB2 (0.48) | F7F3 | |
| SCHEMBL5912617 | 0.80 | F7 (0.75) | F7F3NR4A2NHERF1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | F7 4840/4885F3 2179/4885NR4A2 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.